Free Trial

Pulmatrix (PULM) Competitors

$1.96
-0.04 (-2.00%)
(As of 05/22/2024 ET)

PULM vs. ASLN, BFRI, AIMD, IBIO, HILS, VCNX, TENX, PCSA, KTTA, and SHPH

Should you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include ASLAN Pharmaceuticals (ASLN), Biofrontera (BFRI), Ainos (AIMD), iBio (IBIO), Hillstream BioPharma (HILS), Vaccinex (VCNX), Tenax Therapeutics (TENX), Processa Pharmaceuticals (PCSA), Pasithea Therapeutics (KTTA), and Shuttle Pharmaceuticals (SHPH). These companies are all part of the "pharmaceutical preparations" industry.

Pulmatrix vs.

Pulmatrix (NASDAQ:PULM) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Pulmatrix has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Pulmatrix is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmatrix$7.30M0.98-$14.12M-$2.41-0.81
ASLAN Pharmaceuticals$12M0.61-$44.22M-$2.74-0.16

11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 3.6% of Pulmatrix shares are held by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Pulmatrix had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 2 mentions for Pulmatrix and 1 mentions for ASLAN Pharmaceuticals. Pulmatrix's average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pulmatrix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
ASLAN Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pulmatrix has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.

ASLAN Pharmaceuticals has a net margin of 0.00% compared to Pulmatrix's net margin of -75.73%. Pulmatrix's return on equity of -44.05% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Pulmatrix-75.73% -44.05% -26.71%
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

ASLAN Pharmaceuticals received 4 more outperform votes than Pulmatrix when rated by MarketBeat users. Likewise, 63.49% of users gave ASLAN Pharmaceuticals an outperform vote while only 51.99% of users gave Pulmatrix an outperform vote.

CompanyUnderperformOutperform
PulmatrixOutperform Votes
196
51.99%
Underperform Votes
181
48.01%
ASLAN PharmaceuticalsOutperform Votes
200
63.49%
Underperform Votes
115
36.51%

Pulmatrix presently has a consensus target price of $10.00, indicating a potential upside of 410.20%. ASLAN Pharmaceuticals has a consensus target price of $11.33, indicating a potential upside of 2,411.82%. Given ASLAN Pharmaceuticals' higher possible upside, analysts clearly believe ASLAN Pharmaceuticals is more favorable than Pulmatrix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulmatrix
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

ASLAN Pharmaceuticals beats Pulmatrix on 10 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PULM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PULM vs. The Competition

MetricPulmatrixPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$7.15M$6.64B$5.11B$8.01B
Dividend YieldN/A2.71%2.82%3.91%
P/E Ratio-0.8123.06179.8818.63
Price / Sales0.98190.522,434.8593.56
Price / CashN/A35.9635.9132.25
Price / Book0.385.505.424.62
Net Income-$14.12M$99.33M$105.57M$214.11M
7 Day Performance7.10%0.41%0.25%0.10%
1 Month Performance-2.49%4.96%4.16%5.05%
1 Year Performance-31.23%-5.47%5.21%8.41%

Pulmatrix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ASLN
ASLAN Pharmaceuticals
1.0671 of 5 stars
$0.40
-2.4%
$11.33
+2,733.3%
-88.9%$6.54M$12M-0.1535
BFRI
Biofrontera
2.237 of 5 stars
$1.29
+10.3%
$18.00
+1,295.3%
-89.1%$6.57M$34.07M-0.0883Analyst Revision
Gap Up
AIMD
Ainos
0 of 5 stars
$1.04
-1.9%
N/AN/A$6.51M$122,112.00-0.4146
IBIO
iBio
0 of 5 stars
$1.90
+4.4%
N/AN/A$6.61M$2.38M0.0026Positive News
Gap Down
HILS
Hillstream BioPharma
0 of 5 stars
$0.36
-2.7%
N/A+1.1%$6.42MN/A-0.511Gap Down
VCNX
Vaccinex
1.5671 of 5 stars
$5.51
-0.9%
N/A-93.3%$6.78M$570,000.00-0.0537Positive News
Gap Up
TENX
Tenax Therapeutics
2.2725 of 5 stars
$3.47
-2.3%
$480.00
+13,732.9%
-86.2%$6.80MN/A0.005Analyst Revision
News Coverage
PCSA
Processa Pharmaceuticals
2.9859 of 5 stars
$2.18
-1.8%
$8.00
+267.0%
-86.4%$6.24MN/A-0.4413Gap Down
KTTA
Pasithea Therapeutics
0 of 5 stars
$6.65
-4.3%
N/A-2.9%$6.92M$20,000.000.008Gap Down
SHPH
Shuttle Pharmaceuticals
0 of 5 stars
$0.41
+2.5%
N/A-59.5%$6.96MN/A-0.968News Coverage

Related Companies and Tools

This page (NASDAQ:PULM) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners